HFpEF stands for heart failure with preserved ejection fraction, a heart failure subtype defined by preserved left ventricular ejection fraction with elevated filling pressures. It causes significant symptoms and outcomes despite preserved pump fraction, and is associated with multimorbidity including hypertension, obesity, diabetes, and atrial fibrillation.
Two studies found cardiac MRI-derived biomarkers may improve heart failure risk assessment. Epicardial adipose tissue index was linked to HFpEF risk, while imaging-derived SvO2 predicted hospitalization and death.
Oral semaglutide reduced heart failure events by 22% in Type 2 diabetes patients with existing heart failure in a trial of nearly 9,650 adults, with particular benefit in HFpEF cases.
Edgewise Therapeutics and IDEAYA Biosciences released annual financial reports detailing clinical trial progress and strategic initiatives. Both companies are advancing multiple clinical-stage programs while managing significant operating expenses.
The European Commission has approved a new 7.2 mg once-weekly maintenance dose of Wegovy (semaglutide injection) for adults with obesity, providing physicians with an additional treatment option for patients requiring further weight reduction after the 2.4 mg dose.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07298993 |
Deprescribing Beta-Blockers in Elders With Heart Failure With Preserved Ejection Fraction (DEPRESCRIBE-HFpEF) |
ENROLLING_BY_INVITATION | PHASE4 |
| NCT07270536 |
Accelerated Pacing and Cardiac Filling Pressures During Exercise in Patients With Heart Failure With Preserved Ejection Fraction |
RECRUITING | NA |
| NCT07147114 |
Clinical Trial to Evaluate the Efficacy and Safety in Concomitant Administration of Macitentan and Dapagliflozin in Patients With Heart Failure With Mildly Reduced and Preserved Ejection Fraction (HFmrEF and HFpEF) and Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH) |
RECRUITING | PHASE4 |
| NCT06916611 |
Heart Failure With Preserved Ejection Fraction and Its Cardiac MR Characteristics of Different Subtypes |
ACTIVE_NOT_RECRUITING | |
| NCT06844032 |
Predictors of Poor Prognosis in HFpEF |
RECRUITING | |
| NCT06655480 |
Triple Combination Therapy (ARNI, SGLT2i, MRA) in Advanced HFpEF |
RECRUITING | PHASE2 |
| NCT05115890 |
Muscle Blood Flow Regulation in HFpEF |
RECRUITING | NA |
